About Zhongsheng
Reimagining the Peptide Drug Discovery PlatformAbout Zhongsheng
Hunan Zhongsheng All-Peptide Biotechnology Co., Ltd. is an innovative biotechnology company dedicated to the discovery and development of novel peptide-based therapeutics, with the goal of expanding treatment options for patients worldwide. Founded in September 2017, the company is headquartered in Zhuzhou, China, and maintains subsidiaries in Changsha, China, and New Jersey, USA.
Zhongsheng Quanpeptide boasts a strong talent pool and robust R&D capabilities, with a workforce of over 200 employees, more than 80% of whom are engaged in R&D. The company has also attracted over 20 high‑level overseas returnees. In December 2019, it closed a Series A financing round totaling RMB 100 million; in April 2021, it completed a Series A+ round of RMB 220 million; in July 2025, it secured nearly RMB 100 million in a Series B round; and in May 2026, it raised over RMB 300 million in a Series C round. To date, Zhongsheng Quanpeptide has established R&D collaboration agreements with leading pharmaceutical companies including Novartis, Eli Lilly, AstraZeneca, Jiudian Pharmaceutical, and Kangyuan Pharmaceutical.
Zhongsheng Quanpeptide has established a robust and diversified proprietary peptide library and discovery technology platform, with core therapeutic areas focused on oncology and cardiovascular‑metabolic diseases. The company’s platform supports multiple peptide‑based drug formats, including peptide–radioisotope conjugates (PRCs), peptide–oligonucleotide conjugates (POCs), and peptide–toxin drug conjugates (PDCs).
Corporate Vision
Empowering the thriving development of peptide therapeutics worldwide.
Enabling peptide drugs to benefit patients worldwide at low cost.
Benefit human health
Core Values
Innovation — Innovation is our primary productive force.
Science — Science is the foundation of all innovation.
Patients — the needs of patients are the guiding force behind innovation.
Responsibility — Every study carries the trust of life.
Co-creation — the greatest innovations have never been the achievement of a single individual.
Development History
2026
Completed a Series C funding round exceeding RMB 300 million.
Signed a global licensing agreement with Novartis for a radioligand therapy asset.
Entered into a global R&D collaboration and licensing agreement with Eli Lilly.
2025
Completed a Series B funding round of RMB 63 million.
2023
Selected as a “China National Intellectual Property Advantage Enterprise”
2022
Entered into a research and development collaboration agreement with AstraZeneca.
2021
Selected as a national-level “Little Giant” enterprise specializing in niche fields and demonstrating innovative strength.
Completed a Series A funding round of RMB 220 million.
2020
Selected as a “China High-Tech Enterprise”
2019
Completed a RMB 100 million pre-Series A funding round.
2017
Company establishment
This is the placeholder text for heading one h1.
Contact Us
United States
Scan to follow the official account.
Copyright © Hunan Zhongsheng Quanpeptide Biotechnology Co., Ltd.
Sorry, there is currently no content in this section.
You can view other sections.
Sorry, there is currently no content in the current column
You can check other sections
Business license
Business License